Market Report -- In Play (SHPGY) MSN Money Shire Plc reports study on Vyvanse Capsules CII; also reports it significantly improved ADHD symptoms Co reported results from study evaluating safety and ... Shire spent $150000 lobbying in 1Q BusinessWeek Study Evaluated Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII Efficacy ... MarketWatch (press release) all 22 news articles » |
Court upholds Shire ADHD drug's exclusivity MSN Money The FDA ruled in 2007 Vyvanse qualified as a new chemical entity and was entitled to market exclusivity. That ruling was challenged by Actavis of Iceland. ... |
Excellent Results in a Transformational Year for Shire; Core Product Sales up 25% MSN Money VYVANSE, our leading ADHD treatment with a current monthly US ADHD market share of 13.6%, continues to grow and build strong brand recognition in the US and ... |
Shire says ADHD patch works for adolescents Forbes AP , 10.30.09, 06:01 PM EDT NEW YORK -- Shire PLC says clinical studies show its attention deficit hyperactivity disorder patch Daytrana, which is approved ... Shire Reports Tolerability and Clinical Effects Results of Daytrana(R ... Reuters Market Report -- In Play (SHPGY) MSN Money Shire's ADHD treatment data to be presented at the Honolulu psychiatric meeting News-Medical.net RTT News - istockAnalyst.com (press release) all 44 news articles » |
Market Report -- In Play (SHPGY) MSN Money Shire Pharm: Study published in Child and Adolescent Psychiatry and Mental Health demonstrated once-daily Vyvanse CII provided significant improvement of ... Study Published in Child and Adolescent Psychiatry and Mental ... PR Newswire (press release) all 16 news articles » |